Showing results (21-30 of 119) with videos related to
Sort By:
Pageof 12
PPAR Research|January 15, 2011
Regulation of Immune Responses and Autoimmune Encephalomyelitis by PPARsYuhong Yang, Amy E Lovett-Racke, Michael K RackeNeurology|December 30, 2009
The mechanism of action of glatiramer acetate treatment in multiple sclerosisMichael K Racke, Amy E Lovett-Racke, Nitin J KarandikarArchives of Neurology|September 10, 2008
Monoclonal antibody therapies and neurologic disordersJohn C Novak, Amy E Lovett-Racke, Michael K RackeExpert Review of Clinical Immunology|May 19, 2010
Novel therapeutic strategies targeting the pathogenic T-cells in multiple sclerosisMark T Muir, Amy E Lovett-Racke, Michael K RackeClinical Neuropharmacology|July 15, 2004
Mycophenolate mofetil in multiple sclerosisElliot M Frohman, Kristen Brannon, Michael K Racke, et al.Journal of Neuroimmunology|June 13, 2006
Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytesJihong Xu, Janet A Chavis, Michael K Racke, et al.The Journal of Prevention of Alzheimer'S Disease|January 15, 2026
Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer's disease pathologyYonghong Li, Robert J Lagier, Michael K Racke, et al.Brain, Behavior, and Immunity|December 16, 2014
Analysis of TGF-β1 and TGF-β3 as regulators of encephalitogenic Th17 cells: Implications for multiple sclerosisPriscilla W Lee, Yuhong Yang, Michael K Racke, et al.Journal of Neuroimmunology|May 1, 2022
Changes in ganglioside antibody positivity rates during the COVID-19 pandemicMichael K Racke, Justin K Niles, Raymond A Lorenz, et al.Archives of Neurology|February 16, 2005
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosisNancy L Monson, Petra D Cravens, Elliot M Frohman, et al.Pageof 12